ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ADCT vs PYXS // NET PROFIT MARGIN

ADC Therapeutics SA (NYSE) VS. Pyxis Oncology Inc. (NASDAQ) • 15-METRIC TALLY: ADCT 4 — PYXS 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADCT VS. PYXS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ADCT PYXS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 92.90% 82.80% +10.10 ADCT /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 14.90% -14.20% +29.10 ADCT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 ADCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.3 37.4 +16.90 ADCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $196.6M $202.1M -$5.5M PYXS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ADCT REV PYXS REV ADCT GROSS % PYXS GROSS % ADCT FCF PYXS FCF
FY 2025 $81.4M $13.9M 92.9% 82.8% -$141.4M -$63.5M
FY 2024 $70.8M $16.1M 91.6% 97.1% -$124.7M -$57.9M
FY 2023 $69.1M $230.1M — — -$118.7M -$70.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADCT // BETA —
PYXS // BETA —